TY - JOUR
T1 - Hepatitis C following liver transplantation
T2 - Current approach and future research opportunities
AU - Cosar, Arif M.
AU - Durand, Christine M.
AU - Cameron, Andrew M.
AU - Gurakar, Ahmet
N1 - Publisher Copyright:
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Purpose of review The treatment of hepatitis C virus infection (HCV) in liver transplant recipients was very limited until direct-acting antivirals became widely available. We review the current approach to HCV treatment following liver transplantation and future research opportunities. Recent findings Current treatment of HCV infection with all oral new direct-acting antivirals in the postliver transplant setting is easier, shorter, tolerable, and more effective with high-sustained virological response rates. However, some challenges remain, including the optimal timing of therapy, drug-drug interactions, renal insufficiency, and HIV coinfection. Summary Patients with recurrent HCV following liver transplant will significantly benefit from all oral new direct acting antivirals. Ongoing studies will determine the optimal timing and combination in this unique population.
AB - Purpose of review The treatment of hepatitis C virus infection (HCV) in liver transplant recipients was very limited until direct-acting antivirals became widely available. We review the current approach to HCV treatment following liver transplantation and future research opportunities. Recent findings Current treatment of HCV infection with all oral new direct-acting antivirals in the postliver transplant setting is easier, shorter, tolerable, and more effective with high-sustained virological response rates. However, some challenges remain, including the optimal timing of therapy, drug-drug interactions, renal insufficiency, and HIV coinfection. Summary Patients with recurrent HCV following liver transplant will significantly benefit from all oral new direct acting antivirals. Ongoing studies will determine the optimal timing and combination in this unique population.
KW - current treatment
KW - hepatitis C
KW - liver transplant
UR - http://www.scopus.com/inward/record.url?scp=84969170260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969170260&partnerID=8YFLogxK
U2 - 10.1097/QCO.0000000000000274
DO - 10.1097/QCO.0000000000000274
M3 - Review article
C2 - 27191202
AN - SCOPUS:84969170260
SN - 0951-7375
VL - 29
SP - 346
EP - 352
JO - Current opinion in infectious diseases
JF - Current opinion in infectious diseases
IS - 4
ER -